- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases773
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Nervous System Diseases773
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- PR positive
- PR negative
- ER negative
- p16 positive
- KRAS positive
- PD-L1 negative
- EGFR positive
- EGFR negative
- BRAF positive
- HLA-A positive
- ALK negative
- BRCA1 positive
- BRCA2 positive
- CD20 positive
- IDH positive
- MET positive
- ALK positive
- HLA positive
- p16 negative
- CD19 positive
- IDH negative
- HPV positive
- MYC positive
- PALB2 positive
- ROS1 positive
- HLA negative
- MSI-H positive
- ROS1 negative
- BRAF negative
- NRAS positive
- RET positive
- TP53 positive
- HLA-A negative
- HR positive
- MET negative
- PIK3CA positive
- RB1 negative
- RB1 positive
- dMMR positive
- BRCA positive
- HPV negative
- KIT positive
- BCL2 positive
- RAS positive
- ARID1A positive
- ATM positive
- CCND1 positive
- KRAS negative
- MGMT negative
- NTRK positive
- BCL6 positive
- FLT3 positive
- MMR positive
- NF1 positive
- PTEN positive
- ANA positive
- BRIP1 positive
- CFTR positive
- CHEK2 positive
- HBsAg positive
- HPV16 positive
- MGMT positive
- PD-1 positive
- RAD51 positive
- TP53 negative
- CD30 positive
- FANCA positive
- HR negative
- HRAS positive
- HbSS positive
- MLH1 positive
- MMR negative
- MSH2 positive
- MSH6 positive
- NRAS negative
- NTRK1 positive
- PD-1 negative
- PMS2 positive
- RET negative
- RF positive
- TROP2 positive
- anti-dsDNA positive
- ctDNA positive
- ABCA4 positive
- BARD1 positive
- BCR-ABL1 positive
- BRCA negative
- BRCA1 negative
- BRCA2 negative
- CD123 positive
- CD3 positive
- DLL3 positive
- FMR1 positive
- GRN positive
- HBV DNA negative
- HBsAg negative
- Ki-67 positive
- MECP2 positive
- MSI positive
- MSI-H negative
- MSS negative
- NF2 positive
- RAS negative
- SMN1 positive
- TROP2 negative
- dMMR negative
- p53 positive
- t(11;14) positive
- t(14;16) positive
- t(4;14) positive
- AKT1 positive
- APOL1 positive
- BAP1 positive
- C5 positive
- CD19 negative
- CD33 positive
- CD4 positive
- CD5 positive
- CD8 positive
- CDK12 positive
- CLDN18.2 positive
- CTNNB1 positive
- DMPK positive
- FGFR positive
- FGFR2 positive
- GPC3 positive
- HBV DNA positive
- IAA positive
- KMT2A positive
- MSI negative
- MSS positive
- PDGFRA positive
- PIK3CA negative
- PTEN negative
- Ph positive
- Philadelphia chromosome positive
- RAF positive
- SMARCB1 positive
- SMN2 positive
- STK11 positive
- TERT positive
- TMB positive
- ZnT8 positive
- anti-AChR positive
- anti-Ro autoantibodies positive
- del(17p) positive
- t(14;20) positive
- AChR positive
- AKT negative
- APC positive
- APOE negative
- APOE positive
- APP positive
- AR positive
- ASXL1 positive
- ATR positive
- BCR-ABL positive
- BCR::ABL1 positive
- CA-125 positive
- CCNE1 positive
- CD10 positive
- CD22 positive
- CD30 negative
- CD4 count positive
- CD70 positive
- CDK4 positive
- CHEK1 positive
- COL7A1 positive
- CRLF2 positive
- Complex karyotype positive
- DGM7 positive
- DMD positive
- DNMT3A positive
- EBV positive
- EPCAM positive
- Ex19del positive
- FANCC positive
- FANCD2 positive
- FANCG positive
- FANCL positive
- FAP positive
- FGFR3 positive
- FH positive
- FLT3 negative
- FOXO1 fusion negative
- G719X positive
- H3 K27M positive
- HBB positive
- HBcAb negative
- HBeAg positive
- HRD positive
- HRRm positive
- HbSβ0-thalassemia positive
- IA-2 positive
- IA-2A positive
- ICA positive
- Gleason Score 10
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Alopecia from Prior Anti-Cancer Therapy
- Anemia from Prior Anti-Cancer Therapy
- Anti-Seizure Medications (up to 2 types)
- Antibody-Based Therapy
- Antifibrotic Medications (Nintedanib, Pirfenidone)
- Any Prior Treatment
- Any Treatment for Pancreatic Cancer
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
5679 trials
Columbus, OH (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a drug to see if it's safe and effective to treat a lung disease called Idiopathic Pulmonary Fibrosis.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studied if digital therapies plus standard care can reduce symptoms of schizophrenia in teens & adults.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Graves Disease trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests batoclimab, a medication given as weekly injections under the skin, to see if it can help reduce eye bulging in patients with proptosis. The treatment starts with a higher dose for a few months, followed by a lower dose for a few more months. Batoclimab works by adjusting the immune system to decrease inflammation and swelling around the eyes.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a vaccine to protect older adults from serious E. coli infections. The vaccine trains the immune system to recognize and fight off nine types of harmful E. coli bacteria. In earlier studies, a similar vaccine caused fever and/or diarrhea in some participants and provided limited protection against illness.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug, lanifibranor, to see if it can treat adults with a fatty liver disease called NASH, and who also have liver fibrosis stage 2 or 3.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if a new drug, BHV-3000, is safe and effective in treating migraines in children and adolescents.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if lebrikizumab is effective and safe for adults with chronic sinus and nasal polyps who are already using nasal corticosteroids. The study will take around
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with a specific liver condition called non-cirrhotic NASH/MASH. The patients have significant liver damage but not cirrhosis. EFX aims to improve liver health by reducing swelling and scarring in the liver.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 43 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two treatments for women with moderate to severe acne. One treatment helps balance hormones to reduce skin oiliness, while the other kills bacteria and reduces inflammation. The goal is to see which treatment is more effective and potentially reduce the need for long-term antibiotic use.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Drug Has Already Been Approved
SummaryThis trial seeks to evaluate if CIN-102 can reduce symptoms of diabetic gastroparesis in adults. Participants will compare effects of drug and placebo treatments over 12 weeks.
Get notified when new Irritable Bowel Syndrome trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
Columbus, OH (<10 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called RTA 901 to see if it can help people with nerve pain caused by diabetes. The drug likely works by calming down the nerves that are causing the pain. The study will compare different doses of the drug to find out which dose works best.
1
2
3
…50